In 2006, panitumumab, the first fully human antibody generated from transgenic mice, was approved for clinical use by the US Food and Drug Administration (FDA). Since then, a further seven such antibodies have been approved. In this chapter, we discuss how transgenic mice technologies can provide a powerful platform for creating human therapeutic antibodies. © 2012 Springer Science+Business Media, LLC.
CITATION STYLE
Lee, E. C., & Owen, M. (2012). The application of transgenic mice for therapeutic antibody discovery. Methods in Molecular Biology, 901, 137–148. https://doi.org/10.1007/978-1-61779-931-0_8
Mendeley helps you to discover research relevant for your work.